Home·Stocks·KURA

KURA

Nasdaq

Kura Oncology, Inc.

Basic Materials · Pharmaceutical Preparations

Research view

Fundamentals · SEC EDGAR · FY 2025-12-31

Revenue & Earnings — fiscal year

2023

$53.9M

2024

$67.5M

2025

Snapshot

SEC EDGAR · FY 2025-12-31

Revenue$67.5M

Net Income$-278.7M

Gross Profit—

Oper Income$-303.6M

EPS (dil)$-3.18

Rev/sh$0.76

FCF/sh$-0.80

Book/sh$1.96

Gross M—

Oper M-449.9%

Profit M-412.9%

FCF M-104.8%

ROE-160.0%

ROA-37.7%

ROIC-875.0%

R&D/Rev372.1%

Rev Y/Y25.2%

Rev 3Y CAGR—

EPS Y/Y-57.4%

EPS 3Y CAGR—

FCF 3Y CAGR—

Payout—

Div/sh—

Shs Chg Y/Y+1.8%

Current Ratio6.06

Quick Ratio6.05

Debt/Eq0.06

Int Coverage-200.8×

Net Debt$139.4M cash

Total Debt$9.7M

Cash & Eq$149.1M

Total Assets$738.4M

Oper CF$-64.1M

Capex$6.6M

Free CF$-70.7M

Buybacks—

Equity$174.1M

Liabilities$564.2M

Shs Outstand0.09B

SectorBasic Materials

🔒 P/E—

🔒 Fwd P/E—

🔒 P/S—

🔒 P/B—

🔒 Market Cap—

🔒 Div Yield—

🔒 52W Range—

🔒 Beta—

40+ fundamentals — free from SEC EDGAR (public domain). Only the 🔒 price-derived column needs a market-data feed.

Financials — annual

SEC EDGAR · last 3 FY

USD	FY2023	FY2024	FY2025
Revenue	$0	$53.9M	$67.5M
Gross Profit	—	—	—
Operating Income	$-165.8M	$-193.2M	$-303.6M
Net Income	$-152.6M	$-174.0M	$-278.7M
Diluted EPS	$-2.08	$-2.02	$-3.18
Operating Cash Flow	$-124.8M	$134.3M	$-64.1M
Free Cash Flow	$-125.0M	$133.8M	$-70.7M

COMMUNITY · $KURA0 theses

POST YOUR TAKE →

Ask AI about KURA Build basket with KURA Screener

Fundamentals sourced from SEC EDGAR filings (public domain). For informational purposes only. Not investment advice.